Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDNA CVE:NVH TSE:VSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsVSNVeresenC$0.00C$11.40▼C$19.07C$5.81BN/A1.30 million shs1.15 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%NVHNovoheart0.00%0.00%0.00%0.00%0.00%VSNVeresen0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/AVSNVeresenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideNVHNovoheart 0.00N/AN/AN/AVSNVeresen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ANVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34VSNVeresenN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ANVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/AVSNVeresenN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AVSNVeresenC$1.005.27%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDNAMedicenna TherapeuticsN/A9.579.57NVHNovoheart27.626.136.05VSNVeresenN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDNAMedicenna Therapeutics12.38%NVHNovoheartN/AVSNVeresenN/AInsider OwnershipCompanyInsider OwnershipMDNAMedicenna Therapeutics33.10%NVHNovoheartN/AVSNVeresenN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableVSNVeresen147,000314.00 millionN/ANot OptionableNVH, VSN, IMM, and MDNA HeadlinesRecent News About These CompaniesJordan Cove parent company looks at financing, ownership options, expansionSeptember 28, 2023 | theworldlink.comTELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s errorAugust 27, 2023 | channelnewsasia.comCJordan Cove donates more than $300,000 to defeat measureMay 22, 2023 | theworldlink.comTEncuentran al menos 60 cadáveres en provincia del Congo - ChronApril 26, 2023 | news.google.comNVeresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense WorldApril 18, 2023 | news.google.comNOregon DEQ opens comments on permit renewal for former Weyerhaeuser facilityApril 11, 2023 | theworldlink.comTBidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News AlertsApril 5, 2023 | news.google.comNRecuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News TimesMarch 31, 2023 | news.google.comNThe Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News AlertsMarch 29, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - LexologyMarch 28, 2023 | news.google.comNPembina Pipeline : Gas Infrastructure - Marketscreener.comMarch 27, 2023 | news.google.comNBidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLPMarch 27, 2023 | news.google.comNBBC Sounds - Assignment - Available EpisodesMarch 25, 2023 | bbc.co.ukThe Right of First Refusal and Good Faith in Your Business Contract ... - LexologyMarch 21, 2023 | news.google.comNLiquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital JournalMarch 14, 2023 | news.google.comNNatural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPRMarch 14, 2023 | news.google.comNLong-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLPMarch 9, 2023 | news.google.comNCEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking AlphaMarch 8, 2023 | news.google.comNInsights and Takeaways From Our Top 10 Commercial Litigation ... - LexologyFebruary 28, 2023 | news.google.comNGlobal Natural Gas Market Industry Analysis, Size, Share, Demand ... - Taiwan NewsFebruary 27, 2023 | news.google.comNMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyZscaler Upgraded: Wall Street Forecasts 26% More UpsideBy Gabriel Osorio-Mazilli | June 17, 2025View Zscaler Upgraded: Wall Street Forecasts 26% More UpsideNVH, VSN, IMM, and MDNA Company DescriptionsMedicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Novoheart CVE:NVHC$0.53 +0.01 (+1.92%) As of 11/20/2020Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.Veresen TSE:VSNVeresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
